证券记录 · 已归档季度
ALNY
Alnylam Pharmaceuticals, Inc. · Healthcare · Biotechnology
21被追踪持有人
-1Δ持有人
76.99M持有股份
$25.10B报告持仓市值
+0新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 -4.5% ·
股份流向 -2.9% ·
净新建仓位 -4.8%
· 公式
广泛减持：持股数量下降，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | 0 | 220.72K | $53.70M | n/a | n/a |
| Q2 2026 | 162 | +3 | 107.60M | $32.37B | +7 | −3 |
| Q1 2026 | 161 | -2 | 108.78M | $35.89B | +4 | −7 |
| Q4 2025 | 162 | -2 | 118.83M | $47.26B | +1 | −2 |
| Q3 2025 | 24 | +1 | 85.59M | $39.02B | +2 | −2 |
| Q2 2025 | 21 | -1 | 76.99M | $25.10B | n/a | −1 |
| Q1 2025 | 19 | +2 | 40.24M | $10.86B | +3 | −1 |
| Q4 2024 | 17 | 0 | 41.95M | $9.87B | n/a | n/a |
| Q3 2024 | 16 | +1 | 39.28M | $10.80B | +2 | −1 |
| Q2 2024 | 15 | n/a | 40.30M | $9.79B | n/a | n/a |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 16.81M | +0.3% | $5.48B | 0.8% | ▲ Add | 5 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 15.81M | n/a | $5.15B | 0.3% | n/c | 1 | SEC ↗ ×7 |
| 3 | The Vanguard Group ✦ (被动) | 13.30M | n/a | $4.34B | 0.1% | n/c | 1 | SEC ↗ ×5 |
| 4 | BlackRock ✦ (被动) | 9.98M | n/a | $3.25B | 0.1% | n/c | 1 | SEC ↗ ×22 |
| 5 | Dodge & Cox ✦ | 3.20M | -4.6% | $1.04B | 0.6% | ▼ Trim | 5 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (被动) | 3.17M | -5.8% | $1.03B | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 3.15M | -10.3% | $1.03B | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 8 | Baillie Gifford ✦ | 3.03M | -17.1% | $988.67M | 0.7% | ▼ Trim | 5 | SEC ↗ ×4 |
| 9 | Geode Capital Management ✦ (被动) | 2.40M | +3.3% | $779.86M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 2.08M | -20.5% | $676.88M | 0.1% | ▼ Trim | 5 | SEC ↗ ×8 |
| 11 | Norges Bank ✦ (被动) | 2.03M | -4.8% | $662.84M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 601.20K | +14092.6% | $196.04M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 343.31K | +73.9% | $111.95M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 14 | Marshall Wace ✦ | 238.57K | -11.3% | $77.80M | 0.1% | ▼ Trim | 4 | SEC ↗ ×3 |
| 15 | Point72 Asset Management ✦ | 201.40K | -33.0% | $65.67M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 188.25K | -77.3% | $61.28M | 0.1% | ▼ Trim | 5 | SEC ↗ ×6 |
| 17 | Arrowstreet Capital ✦ | 169.70K | +4085.0% | $55.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 108.28K | -62.6% | $35.31M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 19 | Millennium Management ✦ | 90.44K | -68.5% | $29.49M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 84.39K | -70.1% | $27.52M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 17.79K | +22.5% | $5.80M | 0.0% | ▲ Add | 5 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Soros Fund Management | $16.20M | 曾为 0.4% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 781 持有人, 122.25M 股份, $37.95B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 02
SUPRAN BRYAN
Officer · 1.76K 股 · $398,855
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据